Recently, I’ve had a number of conversations with women who have been told that they have an ovarian cyst or an adnexal mass.
Understandably, this can cause anxiety.
The questions are often very similar:
“Could this be cancer?”
“My CA125 is raised. Should I be worried?”
“Should I have an HE4 test?”
“What are RMI and ROMA?”
Because I’ve found myself having these conversations increasingly often, I wanted to explain some of the things I look at when assessing an ovarian cyst or adnexal mass.
The first thing to say is reassuring:
Most ovarian cysts and adnexal masses are benign.
However, identifying which masses are reassuring, which need surveillance and which require further investigation or specialist referral is extremely important.
At West Wales Women’s Wellbeing, our approach is based on a simple principle:
We don’t rely on one thing.
A blood test, an ultrasound feature or a risk score should not be considered in isolation.
Instead, we bring together your clinical history, menopausal status, specialist in-house ultrasound, recognised ultrasound terminology, risk models, pattern recognition and blood biomarkers where appropriate.
The aim is to build a holistic assessment of your individual risk and, importantly, decide what should happen next.
What is an adnexal mass?
The term adnexal mass can sound worrying, but it simply describes an abnormality arising from the ovary, fallopian tube or surrounding tissues.
There are many possible causes.
These include simple ovarian cysts, haemorrhagic cysts, endometriomas associated with endometriosis, dermoid cysts and many other benign conditions.
A much smaller proportion will represent borderline or malignant disease.
So finding an ovarian mass does not mean that you have ovarian cancer.
The important question is what that particular mass represents and how confident we can be about its nature.
It starts with the ultrasound
A specialist gynaecological ultrasound is at the heart of our assessment.
Modern ultrasound can tell us considerably more than simply whether a cyst is present or how large it is.
We assess the morphology, or architecture, of the mass in detail.
For example:
• Is it a simple fluid-filled cyst?
• Is it unilocular or multilocular?
• Are there solid components?
• Are papillary projections present?
• What does the cyst wall look like?
• What pattern of blood flow is present?
• Is there free fluid?
• What does the other ovary look like?
• Are there other findings within the pelvis?
Just as importantly, we consider how these findings fit together.
Ultrasound terminology and pattern recognition
We use standardised ultrasound terminology, including internationally recognised approaches developed by the International Ovarian Tumor Analysis (IOTA) group.
Why does terminology matter?
Because describing an ovarian mass consistently allows us to move beyond vague terms such as “complex ovarian cyst”.
A detailed description of the morphology of a mass helps us understand what it is likely to represent and enables meaningful risk assessment.
Alongside this structured assessment, specialist ultrasound also involves pattern recognition.
Certain ovarian masses can have characteristic ultrasound appearances. The combination of their shape, internal structure, echogenicity and vascular pattern can provide important clues about their likely pathology.
Pattern recognition is therefore an important part of specialist gynaecological ultrasound, particularly when combined with validated assessment models.
The IOTA ADNEX model
Where appropriate, we can use the IOTA ADNEX model, which stands for Assessment of Different NEoplasias in the adneXa.
ADNEX combines specific clinical and ultrasound features to estimate the probability that an adnexal mass is benign or malignant.
One of its strengths is that it goes beyond a simple “low risk/high risk” answer. The model can provide estimates across different categories of disease, helping add further structure to the ultrasound assessment.
But the same principle applies here as it does to blood tests:
ADNEX is a tool to support clinical assessment, not replace it.
We interpret the result alongside the actual ultrasound images, pattern recognition, your history and other relevant investigations.
What about CA125?
CA125 is probably the blood test most commonly associated with ovarian cancer.
It can be extremely useful, but it is also frequently misunderstood.
CA125 is not, by itself, a test for ovarian cancer.
Some ovarian cancers produce increased amounts of CA125, but many benign conditions can also cause it to rise.
These include conditions such as endometriosis, fibroids, menstruation and pelvic inflammation.
This is particularly important in premenopausal women.
Conversely, a normal CA125 does not completely exclude ovarian malignancy.
So when somebody comes to clinic concerned about an abnormal CA125, we don’t simply look at whether the number is inside or outside the laboratory reference range.
We ask a much more useful question:
What does this CA125 result mean in the context of this woman’s ultrasound, symptoms, menopausal status and overall clinical picture?
What is the RMI?
The Risk of Malignancy Index (RMI) is an established method of estimating the risk associated with an ovarian mass.
It combines three pieces of information:
RMI = Ultrasound score × Menopausal status × CA125
This is important because the RMI does not rely on the CA125 result alone. It incorporates specific ultrasound features and whether a woman is pre- or postmenopausal.
The resulting score can help determine whether further investigation or referral into a specialist pathway is appropriate.
However, an RMI remains a risk assessment, not a diagnosis.
A high RMI does not mean that someone definitely has ovarian cancer, and a low RMI cannot provide an absolute guarantee that a mass is benign.
It is another piece of the overall picture.
What is HE4?
HE4 stands for Human Epididymis Protein 4.
Like CA125, HE4 is a biomarker that can be measured in the blood. Levels may be increased in some epithelial ovarian cancers.
HE4 behaves somewhat differently from CA125, which means that in selected situations it can provide additional information.
This can be particularly useful when CA125 is difficult to interpret in isolation.
But HE4 has limitations too.
Its level can be affected by factors including age and kidney function, and an elevated HE4 does not diagnose ovarian cancer.
It needs context.
What is ROMA?
This brings us to another acronym that women are increasingly encountering: ROMA.
ROMA stands for the Risk of Ovarian Malignancy Algorithm.
It combines:
CA125 + HE4 + menopausal status
These factors are used within an algorithm to classify the risk associated with an adnexal mass.
This is quite different from the RMI.
RMI uses:
Ultrasound + CA125 + menopausal status
ROMA uses:
HE4 + CA125 + menopausal status
ROMA therefore adds information from a second biomarker, HE4, but does not directly incorporate the detailed ultrasound appearance of the mass.
ROMA is also not an ovarian cancer screening test for women who do not have an adnexal mass.
And, importantly, a higher-risk ROMA result does not mean that ovarian cancer has been diagnosed.
It tells us something about risk.
RMI, ROMA or ADNEX: which is best?
This is perhaps the wrong question.
Each looks at the problem from a slightly different angle.
RMI combines a relatively simple ultrasound score with CA125 and menopausal status.
ROMA combines two biomarkers, CA125 and HE4, with menopausal status.
ADNEX uses much more detailed information about the ultrasound appearance of the mass alongside clinical information, with CA125 incorporated where appropriate.
And then there is the clinician’s pattern recognition, interpreting what the mass actually looks like in real time.
Rather than placing all our confidence in one number, at WWWW we prefer to ask:
Do all the different pieces of information tell a consistent story?
That is a much more useful clinical question.
Putting the pieces together
Our comprehensive adnexal mass assessment therefore brings together several different layers of information.
Your story
Your symptoms, age, menstrual or menopausal status, medical and family history, previous imaging and how the mass was discovered.
Specialist ultrasound
A detailed in-house gynaecological ultrasound assessing the morphology and vascularity of the mass and the remainder of the pelvis.
Standardised terminology
Using recognised ultrasound terminology so that the features of the mass are described systematically rather than simply labelling it a “complex cyst”.
Pattern recognition
Considering whether the combination of ultrasound appearances suggests a recognisable benign or malignant pattern.
Validated risk assessment
Using models such as IOTA ADNEX or RMI where appropriate.
Biomarkers
Interpreting CA125 and, in selected circumstances, additional markers such as HE4 and ROMA within the wider clinical picture.
It is the combination that matters.
What happens after the assessment?
The purpose of all of this is not simply to generate another score.
It is to answer the question that actually matters:
What should we do next?
For some women, the ultrasound appearances are reassuring and no further investigation may be required.
For others, repeating an ultrasound after an appropriate interval may be recommended.
Sometimes additional blood tests, further imaging or another specialist opinion is helpful.
And occasionally the safest recommendation is referral into an NHS specialist gynaecology or gynaecological oncology pathway.
A good assessment should therefore provide more than a description of an ovarian cyst.
It should provide a clear clinical plan.
“So, should I worry about my ovarian cyst?”
In most cases, an ovarian cyst will ultimately prove to be benign.
But understandably, being told that you have an ovarian mass can create considerable uncertainty, particularly if you have also received an abnormal blood result.
Our approach is not to provide reassurance based on one number alone.
Nor do we believe that simply ordering more blood tests necessarily provides a better answer.
Instead, we bring together specialist ultrasound, recognised ultrasound terminology, pattern recognition, validated risk models such as ADNEX and RMI, and biomarkers including CA125 and, where appropriate, HE4 and ROMA.
This allows us to develop a more complete, individualised assessment of risk.
Because ultimately the most useful question isn’t:
“Is my CA125 normal?”
or:
“What is my ROMA score?”
It is:
“When we put everything together, what does my ovarian mass most likely represent, what is my individual risk, and what should happen next?”
That is the question a comprehensive adnexal mass assessment should help answer.
